Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
about
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.Practical review of immunizations in adult patients with cancer.Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.Pneumococcal conjugate vaccine use in adults.HIV-related pneumococcal disease prevention in adults.Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA).Immunization of HIV-infected adult patients - French recommendations.Stimulating Evidence for Pneumococcal Conjugate Vaccination Among HIV-Infected Adults.Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.Summary of NACI Statement: Interim Recommendations on the Use of Pneumococcal Vaccines in Immunocompetent Adults 65 Years of Age and Older.
P2860
Q35907519-D5D50295-E221-4D3F-9171-CEBD8A68F951Q36040140-5329E524-5355-4763-861E-EAF199568D0EQ36388960-CC26F2ED-98FB-414A-B2BF-D1507836761CQ36523805-46BACFD3-D03D-494D-8F94-B5B148B3A4ABQ36873030-C92900F4-D199-4BC9-9FF3-21C7821AEBB7Q37197079-48625C1F-E0C4-4547-8123-F599F842B691Q38560859-15EDCF62-AA59-49A0-8383-071EDF63EB47Q38639401-7CB7B42E-FDD9-4BF9-9C99-ED2C3DC6B51AQ38664425-05FB9A2E-E391-4D52-8A13-7C56A99B8BB7Q38947827-45355722-759B-4BD3-9C9D-1EFCBD9C4CB9Q38987500-6C74D2F0-528B-4FFD-A04A-7782D2021A49Q40615516-BE43CDA5-B69C-4F18-82E1-94300E2F4769Q45979911-8F982CA1-7BC5-4E94-B339-21A310CBBE14Q48222344-C871DDED-1B4B-4876-9789-8473FD3E7A99Q55239802-051F6CBD-A232-4349-B532-DD553A05E1B3
P2860
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Immunogenicity and Safety of 1 ...... coccal Polysaccharide Vaccine.
@en
type
label
Immunogenicity and Safety of 1 ...... coccal Polysaccharide Vaccine.
@en
prefLabel
Immunogenicity and Safety of 1 ...... coccal Polysaccharide Vaccine.
@en
P2093
P2860
P356
P1476
Immunogenicity and Safety of 1 ...... coccal Polysaccharide Vaccine.
@en
P2093
Alejandra Gurtman
Beate Schmoele-Thoma
Cynthia Brinson
Daniel A Scott
Daniel Skiest
Emilio A Emini
Jacob P Lalezari
Marshall J Glesby
Richard N Greenberg
Robert Natuk
P2860
P356
10.1093/INFDIS/JIU631
P407
P577
2014-11-13T00:00:00Z